ROMEO (Rosuvastatin in Metabolic syndrOme)
Study identifier:D3560L00061
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A 6-week, randomised, open-label, parallel group, multi-centre study to compare the efficacy of rosuvastatin 10mg with atorvastatin 10mg in the treatment of metabolic syndrome subjects with raised LDL-C
Medical condition
Metabolic Syndrome X
Phase
Phase 4
Healthy volunteers
No
Study drug
Rosuvastatin, Atorvastatin
Sex
All
Actual Enrollment
258
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Sept 2006
Primary Completion Date: 01 Jun 2008
Study Completion Date: 01 Jun 2008
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Jun 2011 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: Rosuvastatin | Drug: Rosuvastatin 10mg Other Name: Crestor |
| Active Comparator: Atorvastatin | Drug: Atorvastatin 10mg |
Contacts
Investigators
Principal Investigator
JoonWoo Bahn
AstraZeneca
